Caldwell Sutter Capital, Inc. Celldex Therapeutics, Inc. Transaction History
Caldwell Sutter Capital, Inc.
- $215 Billion
- Q4 2024
A detailed history of Caldwell Sutter Capital, Inc. transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Caldwell Sutter Capital, Inc. holds 350 shares of CLDX stock, worth $6,975. This represents 0.0% of its overall portfolio holdings.
Number of Shares
350
Previous 350
-0.0%
Holding current value
$6,975
Previous $11.9 Million
25.65%
% of portfolio
0.0%
Previous 0.01%
Shares
1 transactions
Others Institutions Holding CLDX
# of Institutions
197Shares Held
60.7MCall Options Held
960KPut Options Held
675K-
Kynam Capital Management, LP Princeton, NJ5.06MShares$101 Million8.11% of portfolio
-
Black Rock Inc. New York, NY4.69MShares$93.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.88MShares$77.4 Million0.0% of portfolio
-
Eventide Asset Management, LLC Boston, MA3.75MShares$74.8 Million1.82% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.56MShares$70.9 Million0.01% of portfolio
About Celldex Therapeutics, Inc.
- Ticker CLDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,772,400
- Market Cap $932M
- Description
- Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...